Technical Analysis for ADMS - Adamas Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 11.1 -1.25% -0.14
ADMS closed up 5.24 percent on Wednesday, February 20, 2019, on 1.18 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Feb 28

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical ADMS trend table...

Date Alert Name Type % Chg
Feb 20 Pocket Pivot Bullish Swing Setup -1.25%
Feb 20 Upper Bollinger Band Walk Strength -1.25%
Feb 20 Weak + Overbought Other -1.25%
Feb 20 Wide Bands Range Expansion -1.25%
Feb 20 Above Upper BB Strength -1.25%
Feb 20 Overbought Stochastic Strength -1.25%
Feb 20 Up 3 Days in a Row Strength -1.25%
Feb 20 Up 4 Days in a Row Strength -1.25%
Feb 20 Up 5 Days in a Row Strength -1.25%
Feb 20 Upper Bollinger Band Touch Strength -1.25%

Older signals for ADMS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Adamas Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for chronic disorders of the central nervous systems (CNS) in the United States. The company is developing its lead product candidate, ADS-5102 that has completed a Phase 2/3 clinical study for levodopa induced dyskinesia, a complication of Parkinson's disease; and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. It is also developing ADS-8800 and ADS-9000 series of products for use in a range of CNS indications; ADS-8704, a fixed-dose combination of memantine and donepezil for the treatment of moderate to severe dementia related to alzheimer's disease; and ADS-8902, a triple combination antiviral drug therapy for influenza. In addition, the company develops memantine-based therapeutics portfolio includes Namenda XR and MDX-8704, which are used in the treatment of dementia associated with moderate to severe alzheimer's disease. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Chemical Compounds Alzheimer's Disease Influenza Parkinson's Disease Dementia Psychiatry Psychiatric Diagnosis Treatment Of Alzheimer's Disease Cognitive Disorders Drug Therapy Chronic Disorders Learning Disabilities Traumatic Brain Injury
Is ADMS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 32.9
52 Week Low 7.42
Average Volume 542,508
200-Day Moving Average 18.7378
50-Day Moving Average 9.0367
20-Day Moving Average 9.2418
10-Day Moving Average 9.671
Average True Range 0.5359
ADX 20.6
+DI 33.4244
-DI 9.269
Chandelier Exit (Long, 3 ATRs ) 9.6423
Chandelier Exit (Short, 3 ATRs ) 9.8577
Upper Bollinger Band 10.7237
Lower Bollinger Band 7.7599
Percent B (%b) 1.17
BandWidth 32.06951
MACD Line 0.3702
MACD Signal Line 0.1046
MACD Histogram 0.2656
Fundamentals Value
Market Cap 253.06 Million
Num Shares 22.5 Million
EPS -2.99
Price-to-Earnings (P/E) Ratio -3.76
Price-to-Sales 2373.51
Price-to-Book 4.03
PEG Ratio -0.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.07
Resistance 3 (R3) 11.98 11.61 11.93
Resistance 2 (R2) 11.61 11.40 11.66 11.88
Resistance 1 (R1) 11.43 11.27 11.52 11.52 11.84
Pivot Point 11.06 11.06 11.11 11.11 11.06
Support 1 (S1) 10.88 10.85 10.97 10.97 10.64
Support 2 (S2) 10.51 10.72 10.56 10.60
Support 3 (S3) 10.33 10.51 10.55
Support 4 (S4) 10.42